Eisai gains option to novel cancer therapy, licenses out antifungal

In a flurry of licensing activity, Eisai has acquired an option to a novel targeted cancer therapy from a Japanese bioventure and has awarded the rights to an antifungal prodrug in Japan to a small local firm.